Business
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
– Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"– Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk Patients with Autoimmune or Inflammatory Diseases (AIID) Similarly to Those Without AIID – ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of two post-hoc analyses from CLEAR Outcomes focused on risk of ischemic stroke and risk of major adverse cardiovascular events (MACE) in patients with autoimmune or inflammatory diseases. These data were presented as moderated poster presentations at the American College of Cardiology’s Annual Scientific Session (ACC.26) which took place March 28-30, 2026, in New Orleans, LA. “These analyses provide important insights into how bempedoic acid performs in high-risk patient populations,” said Luke Laffin, MD, senior author of the CLEAR Outcomes sub analyses and Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. “Patients with autoimmune and inflammatory diseases face a significantly elevated cardiovascular burden, and these data reinforce that bempedoic acid delivers meaningful reductions in cardiovascular events in this vulnerable group. In addition, when we examine ischemic stroke patients specifically, this analysis shows a clear and clinically relevant reduction in risk for statin intolerant patients. Together, these findings underscore the value of bempedoic acid as an effective, well tolerated therapy for reducing cardiovascular risk across diverse patient populations.” “These new analyses from CLEAR Outcomes further strengthen the evidence base supporting NEXLETOL as a proven therapy for cardiovascular risk reduction - especially for patients who cannot tolerate statin therapy,” said Sheldon Koenig, President and Chief Executive Officer of Esperion. “The consistency of benefit observed in high-risk populations, including those with autoimmune or inflammatory diseases, highlights the broad clinical relevance of bempedoic acid. We are proud to continue expanding the data that informs treatment decisions and supports the recent incorporation of bempedoic acid into U.S. dyslipidemia guidelines.” Key data presented at ACC.26 Bempedoic acid and incidence of stroke among stat...